Gsa Capital Partners LLP Syros Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

  • $1.32 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 09, 2022
SELL
$0.69 - $1.21 $256,823 - $450,371
-372,208 Closed
0 $0
Q1 2022

May 11, 2022
BUY
$1.02 - $3.8 $132,677 - $494,288
130,076 Added 53.72%
372,208 $443,000
Q4 2021

Feb 14, 2022
BUY
$3.26 - $4.66 $429,651 - $614,164
131,795 Added 119.45%
242,132 $789,000
Q3 2021

Nov 12, 2021
SELL
$4.08 - $5.66 $125,068 - $173,501
-30,654 Reduced 21.74%
110,337 $493,000
Q2 2021

Aug 05, 2021
BUY
$5.01 - $7.48 $381,566 - $569,684
76,161 Added 117.48%
140,991 $768,000
Q1 2021

May 10, 2021
BUY
$7.19 - $14.95 $466,127 - $969,208
64,830 New
64,830 $485,000
Q1 2020

May 12, 2020
SELL
$4.46 - $9.2 $123,791 - $255,355
-27,756 Closed
0 $0
Q4 2019

Feb 12, 2020
BUY
$4.52 - $10.1 $125,457 - $280,335
27,756 New
27,756 $192,000
Q3 2019

Nov 12, 2019
SELL
$7.14 - $11.65 $143,299 - $233,815
-20,070 Closed
0 $0
Q2 2019

Aug 06, 2019
SELL
$5.5 - $9.75 $101,711 - $180,306
-18,493 Reduced 47.96%
20,070 $186,000
Q1 2019

May 15, 2019
SELL
$5.51 - $9.59 $77,217 - $134,394
-14,014 Reduced 26.65%
38,563 $352,000
Q4 2018

Feb 12, 2019
SELL
$5.55 - $11.34 $159,840 - $326,592
-28,800 Reduced 35.39%
52,577 $293,000
Q3 2018

Nov 13, 2018
BUY
$9.74 - $12.92 $411,028 - $545,224
42,200 Added 107.72%
81,377 $969,000
Q2 2018

Aug 09, 2018
SELL
$10.16 - $13.65 $708,385 - $951,718
-69,723 Reduced 64.02%
39,177 $400,000
Q1 2018

May 11, 2018
BUY
$9.47 - $12.98 $1.03 Million - $1.41 Million
108,900 New
108,900 $1.41 Million
Q4 2017

Feb 14, 2018
SELL
$8.45 - $17.48 $137,735 - $284,924
-16,300 Closed
0 $0
Q3 2017

Nov 20, 2017
BUY
$13.52 - $23.75 $220,376 - $387,125
16,300
16,300 $240,000

About Syros Pharmaceuticals, Inc.

SYRS Quotes by TradingView
  • Ticker SYRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,236,200
  • Market Cap $5.87M
  • Description
  • Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...
More about SYRS
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email